Onychodystrophy associated with dupilumab therapy for atopic dermatitis

Abstract

Atopic dermatitis (AD) is a chronic inflammatory disorder affecting the skin and is characterized by a type 2 inflammation, including type 2 helper CD4+ T cells, interleukin 4 (IL-4), IL-5, and IL-13.1 Dupilumab is a monoclonal antibody that blocks IL-4 and IL-13 signaling by binding to the IL-4 receptor alpha subunit that is shared by both IL-4 and IL-13 receptors. Treatment of AD by dupilumab has been shown to be efficacious, with long-term benefit.2 Unique dupilumab-associated side effects in patients with AD have been reported, including conjunctivitis2 and head and neck dermatitis3 caused by unknown mechanisms.

Topics & Concepts